India pharma units fare better in US checks in 2023

The drug regulator United States Food and Drug Administration (USFDA) has classified 13%, or 19 out of 145 inspections it carried out against Indian facilities, as Official Action Indication (OAI) in 2023, which is lower than the global average of 15% OAIs, according to a report by Indian Pharmaceutical Alliance and McKinsey & Company said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/12gmDGe
via IFTTT